How many studies have been conducted on Batroxobin?

BiohacksAI has indexed 300 PubMed studies on Batroxobin, including 18 randomized controlled trials (RCTs). 32% of studies involve human subjects.

What are the main research areas for Batroxobin?

The primary research domains for Batroxobin are ❤️ Cardiovascular, 🦴 Bone & Joint, 🔬 Oncology. This is based on analysis of 300 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Batroxobin

A proteolytic enzyme obtained from the venom of fer-de-lance (BOTHROPS ATROX). It is used as a plasma clotting agent for fibrinogen and for the detection of fibrinogen degradation products. The presence of heparin does not interfere with the clotting test. Hemocoagulase is a mixture containing batroxobin and factor X activator. EC 3.4.21.-.

300+ PubMed studies analyzed · 18 RCTs · Evidence Score: 47.1

Research Domains

Batroxobin has been studied across 18 research domains including ❤️ Cardiovascular, 🦴 Bone & Joint, 🔬 Oncology, 🧠 Focus & Attention, 🫁 Liver & Detox. The primary research focus is ❤️ Cardiovascular with 8% of studies addressing this area.

Loading evidence profile...

This evidence profile for Batroxobin is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.